biosimilars
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
FDA releases biosimilars labelling guidance
April 1, 2016Manufacturing and Production, Medical Communications, Research and Development FDA, biosimilars
The US Food and Drug Administration (FDA) has issued draft guidance on the labelling of biosimilar drugs. The guidance states …
Samsung Bioepis’ Remicade biosimilar set for CHMP verdict
March 31, 2016Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab
Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
Biosimilars could save healthcare systems $100bn by 2020
March 30, 2016Research and Development, Sales and Marketing biosimilars
The growth of the market for biosimilar drugs has the potential to save EU and US healthcare systems up to …
Amgen sues Novartis over Enbrel biosimilar
March 3, 2016Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
Merck begins late-stage trials of Humira biosimilar
March 2, 2016Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars
Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
Sandoz buys rights to Pfizer biosimilar
February 12, 2016Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars
Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …
Sandoz’s Carol Lynch elected to chair European Biosimilars Group
February 10, 2016Medical Communications biosimilars
The European Generic Medicines Association (EGA) has elected Carol Lynch, global head of Biopharmaceuticals & Oncology Injectables at Sandoz, as …
FDA set to approve Remicade biosimilar
February 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima
An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
NICE backs biosimilars with arthritis drug endorsements
January 27, 2016Research and Development, Sales and Marketing DMARDs, NICE, biosimilars, rheumatoid arthritis
NICE has published updated final guidance recommending seven biological disease modifying drugs (DMARDs) for treatment of severe rheumatoid arthritis which …
Mylan announces Momenta collaboration to develop six biosimilars
January 8, 2016Manufacturing and Production, Sales and Marketing Heather Bresch, Momenta, Mylan, biosimilars
Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …
Seven pharma trends for 2016
December 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2016?Pricing pressures
Sandoz announces biosimilar successes
December 8, 2015Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim
Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …
EU plans export waiver for pharma manufacturing
November 3, 2015Manufacturing and Production EGA, European Commission, biologics, biosimilars, generics, manufacturing, supplementary protection certificates
The European Commission plans to bring in an export waiver for supplementary protection certificates, in order to boost pharma industry …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
